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example comparing infusional 5FU/FA+oxaliplatin with bolus
5FU/FA+irinotecan.
As NICE has now approved irinotecan as second-line therapy,
there is a concern that in FOCUS the crossover for patients will be
asymmetric. Patients initially having oxaliplatin could expect to
crossover (i.e. receive irinotecan as salvage therapy), whereas those
initially on irinotecan would not be able to crossover to oxaliplatin,
as it is not licensed or approved in this indication. To address this
situation the Trial Management Group (TMG) has suggested that,
in those patients fit enough to receive it, a planned crossover
treatment be designed. The TSC approved this request at their
meeting on 19th June, and this will be implemented as soon
as possible. This will ensure that every patient entering FOCUS
will potentially have access to irinotecan and oxaliplatin at some
point.
The TSC, DMEC and TMG believe that FOCUS remains a key
trial despite the studies quoted in your editorial. We support its
continued accrual, and encourage existing participants and new
centres to enter patients. Only in this way can we clarify the use
and sequencing of combination chemotherapy as quickly as
possible.
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Sir,
In our editorial ‘Why hasn’t the National Institute been NICE to
patients with colorectal cancer’, we highlighted the disparity of
treatment in England and Wales compared to other industrialised
countries, particularly with respect to the poor 5-year survival
figures. Our concerns focused on the conclusions reached by the
NICE panel in the face of two prospective, randomised trials
involving more than 1000 patients showing a survival advantage in
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Saltz et al, 2000).
We only referred to the MRC CRO8 (FOCUS) study since the
NICE panel recommended entering patients into this trial and were
planning to review their guidance when the results from this study
are available. We never questioned the ethical validity of the
FOCUS study. We simply pointed out that NICE seem to have
linked their guidance very closely to this study and feel that they
have frankly misinterpreted the many positive studies from here
and abroad. NICE also failed to appreciate that patients who were
randomised into the two oxaliplatin arms were unable to receive
irinotecan at any point, even though they supported second-line
use of this drug. We were not questioning the FOCUS study; we
simply alluded to this disparity created by NICE. Since our
editorial was published, the FOCUS study has, in our opinion,
quite rightly added a third-tier of treatment, so allowing all
patients to receive both oxaliplatin and irinotecan at some point.
However, according to NICE recommendations, patients who
prefer not to be entered into this study should only receive 5-
Fluorouracil and folinic acid (5FU/FA) ‘up-front’, unless they fall
into the very small group of patients that have potentially operable
liver metastases.
With the widespread availability of the internet and because we
need to provide enough information to allow patients to give
informed consent, they are quite rightly questioning the NICE
guidance in a similar manner to the 28 colorectal oncologists who
wrote to the Daily Telegraph in June. Patients are also rightly
concerned that the NICE guidance was influenced too much by
government funding constraints rather than clinical-effectiveness.
We would strongly urge NICE to consider a fresh review before
2005, based on both the convincing existing data (Douillard et al,
2000; Saltz et al, 2000) and the rapidly emerging new data using all
three drugs – planned or unplanned (Tournigand et al, 2001;
Goldberg et al, 2002).
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Sir,
Drs Mason, Johnson and Rudd suggest that criticism of the
guidance issued by the National Institute for Clinical Excellence
(NICE) regarding the use of irinotecan and oxaliplatin in the
treatment of patients with advanced colorectal cancer may have
implications for the FOCUS trial (Cunningham et al, 2002; Mason
et al, 2002; NICE, 2002; Saunders and Valle, 2002). However, the
reason for criticism of the NICE guidance is due to the
overwhelming evidence that access to the three drugs 5-
fluorouracil, irinotecan and oxaliplatin is the optimal therapeutic
approach to metastatic colorectal cancer. Subsequent to this
guidance entry into the revised FOCUS protocol is the only way
that patients in the UK can access all these agents. Therefore,
patients not participating in the FOCUS trial will receive
suboptimal therapy. Although the median survival for FOCUS
of 16 months is encouraging, and certainly a major step forward
over CRO6 with a median survival of approximately 10 months
(Maughan et al, 2002), it remains significantly less than that
for patients treated with all three agents in randomised trials such
as N9741 (Goldberg et al, 2002) and the Tournigand trial
(Tournigand et al, 2001) with median survivals of 18.6 months
(data presented at the American Society of Clinical Oncology,
Orlando, 2002) and approximately 21 months (data presented
at the American Society of Clinical Oncology, San Francisco,
2001).
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